Nimbus is back for more, raising $210M to fuel pipeline seven months after $4B Takeda deal
What kind of biotech company returns billions to its investors without ever opening a lab, commercializing a drug, or going public with an IPO?
Nimbus Therapeutics. After raising $125 million just a year ago and selling a still-experimental pill to Takeda Pharmaceutical in a deal earlier this year that could be worth as much as$6 billion, the small Boston-based biotech is back for more.
On Wednesday, Nimbus announced that it raised $210 million in private financing, including from first-timer GV (formerly known as Google Ventures) and returning investors that include SR One, Atlas Venture, and Gates Frontier — Bill Gates’ venture capital firm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.